Anistreplase (Anisoylated Plasminogen Streptokinase Activator Complex, Apsac) in Coronary Thrombolysis
Reference18 articles.
1. Smith RAG, Dupe RJ, English PD, Green J. Thrombolysis with acyl enzymes: A new approach to thrombolytic therapy. Nature (Lond) 290:505, 1981.
2. Been M, de Bono DP, Muir AL, Boulton FE, Hillis WS, Hornung R. Coronary thrombolysis with intravenous anisoylated plasminogen streptokinase activator complex BRL 26921. Br Heart J 53:253, 1985.
3. Been M, de Bono DP, Muir AL, Boulton FE, Fears R, Standring R, Ferres H. Clinical effects and pharmaco-kinetics of intravenous APSAC (anisoylated plasminogen streptokinase activator complex, BRL26921) in acute myocardial infarction. Int J Cardiol 11:53, 1986.
4. Anderson JL, Rothbard RL, Hackworthy RA, et al. Multicenter reperfusion trial of intravenous anisoylated plasminogen streptokinase activator complex (APSAC) in acute myocardial infarction. Controlled comparison with intracoronary streptokinase. J Am Coll Cardiol 11:1153, 1988.
5. Bonnier HJRM, Visser RF, Klomps HC, Hoffman HJML, and the Dutch Invasive Reperfusion Study Group. Comparison of intravenous anisoylated plasminogen streptokinase activator complex and intra-coronary streptokinase in acute myocardial infarction. Am J Cardiol 2:25, 1988.